We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PRZO:NASDAQParaZero Technologies Ltd. Analysis

Data as of 2026-06-14 - not real-time

$0.60

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ParaZero Technologies Ltd. (PRZO) is trading well below its 20‑day SMA and 50‑day SMA, with the RSI hovering just under the 50‑point neutral zone, indicating a modest bearish bias. The MACD histogram is negative and the signal line is bearish, reinforcing downside momentum, while volume trends are slipping, suggesting waning trader interest.
Recent material news – a new full‑scale production line for DefendAir and the receipt of a Tier‑1 U.S. defense order – provide a tangible operational catalyst that could lift demand, yet the company still posts zero profit margin, negative EBITDA and a steep max‑drawdown, keeping the short‑term outlook cautious. Over the medium horizon, the defensive sector positioning and the first order hint at potential revenue uplift, but the balance sheet remains thin (high debt‑to‑equity, negative operating cash flow) and the price‑to‑book ratio of 3.7 flags an overvalued market perception. Long‑term, the lack of dividend, persistent operating losses and high beta (≈2.3) suggest that any upside will hinge on successful scaling of the new production capacity and conversion of orders into sustainable cash flow.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • bearish MACD and RSI below neutral
  • decreasing volume trend
  • high 30‑day volatility (~150%) and steep max drawdown

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • new production capacity for DefendAir
  • first Tier‑1 U.S. defense order
  • still negative earnings and cash flow

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • high beta (~2.3) indicating market sensitivity
  • price‑to‑book ratio >3 suggests overvaluation
  • absence of dividend and ongoing operating losses

Key Metrics & Analysis

Financial Health

Revenue Growth6.00%
ROE-380.47%
ROA-85.43%
Debt/Equity9.71
P/B Ratio3.7
Op. Cash Flow$-5804052
Free Cash Flow$-3259947
Industry P/E30.6

Technical Analysis

TrendBearish
RSI44.9
Support$0.45
Resistance$1.18
MA 20$0.63
MA 50$0.67
MA 200$1.14
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta2.29
Volatility150.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.